CLINICAL_TRIALS
trial_result
· 2020-04-01
Clinical Trial Update: Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer [Phase 2]
Summary
Phase 2 study evaluating the combination of interleukin-2 and pembrolizumab in metastatic renal cell carcinoma has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-04-01